CSC Financial analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$147.70.Memorial Day Sale – Claim 55%...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innovent Biologics with a HK$120.45 average price target.
The company has a one-year high of HK$109.10 and a one-year low of HK$61.00. Currently, Innovent Biologics has an average volume of 12.78M.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
Innovent, Pfizer sign oncology deal
China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials
In a report released on May 28, from Morgan Stanley maintained a Buy rating on Innovent Biologics, with a price target of…
In a report released yesterday, from Zhongtai Securities maintained a Buy rating on Innovent Biologics, with a price target of…
LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Inhibrx Biosciences Inc today and set a price target of…
In a report released on June 25, from UBS maintained a Buy rating on InSilico Medicine Cayman TopCo, with a price target of…
In a report released yesterday, from CICC maintained a Buy rating on BOC Hong Kong (Holdings), with a price target of…
In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of…
